First-in-human clinical trial testing CRISPR/Cas9 gene-editing in 12 highly metastatic, end-stage GI cancer patients saw several of their cancer growth halt, and one patient had a complete response - metastatic tumors disappeared over course of several months and have not returned in over two years.